Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Prospective Clinical Advantages Of Trabecular Metal(TM) Technology Highlighted In Comparative Study
Zimmer Holdings, Inc. (NYSE: ZMH; SWX: ZMH) announced that data from a comparative clinical study conducted by researchers at the Mayo Clinic and the Joint Replacement Surgeons of the Indiana Research Foundation describes the low stiffness and osteoconductive properties of Zimmer"s Trabecular Metal Technology. The study, published in The Journal of Arthroplasty, found significant reductions in acetabular bone loss adjacent to the Trabecular Metal device compared to the titanium component, and a significant relative increase in bone mineral density (BMD) after total hip arthroplasty (THA) using implants made with Zimmer"s proprietary Trabecular Metal Technology.
generic viagra online
In Pediatric Patients Sleep Disorders Are Largely Underdiagnosed
Primary care pediatricians may be under-diagnosing sleep disorders in children and teens, according to a research abstract presented on June 8 at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies.
News of the day
Cobalis Corporation Is Awarded Two New International Patents In Canada And Mexico For Its Revolutionary Anti-Allergy Relief Product PreHistin(R)
Cobalis Corporation (OTC:CLSC) was recently awarded two additional International Patents in Canada and Mexico and has a patent pending application in Japan. PreHistin® is patented, safe for long-term daily use and available without a prescription. It is available in a cherry flavored, all natural, proprietary cyanocobalamin (vitamin B12) sub-lingual lozenge that is taken twice daily to regulate allergy sufferers" response to both indoor and outdoor allergens with daily and year round usage.
Diagnostics

Active Biotech's Cancer Project ANYARA Featured In Journal Of Clinical Oncology

The Journal of Clinical Oncology (DOI: 10.1200/JCO.2008.20.2515) releases an article covering Active Biotech"s (NASDAQ OMX Nordic: ACTI) cancer project ANYARA, where ANYARA was studied both as a single agent and in combination with an established tumor therapy - docetaxel (Taxotere®) - in patients with advanced cancer. Two parallel Phase I studies1) were performed, one monotherapy study (including 39 patients with non-small cell lung cancer (NSCLC), pancreatic cancer (PC) or renal cell cancer (RCC)) with ANYARA and one study in combination with docetaxel (13 patients with NSCLC), in order to assess the safety, tolerability and pharmacology of ANYARA. The results showed that ANYARA was well tolerated both as monotherapy and in combination with docetaxel. ANYARA showed immunological activity including systemic increase in inflammatory cytokines, selective expansion of ANYARA reactive T-cells and induction of tumor infiltrating T-cells. Anti-tumor activity was assessed and in the mono study fourteen patients (36%) had Stable Disease (SD) after two months. In the combo study the best overall response was confirmed Partial Response (a tumor reduction of at least 30 percent), for 2 patients (15%) and SD for 5 patients (38%). ANYARA is presently in development primarily for the treatment of renal cell cancer. A pivotal phase III study, which has completed enrollment of over 500 patients, is currently ongoing. Active Biotech AB (publ) Tomas Leanderson President & CEO 1) Previously presented in summary in press releases: December 13, 2006 "Active Biotech"s Novel Cancer Treatment ANYARA Shows Pharmacological Proof of Concept after Successful Phase I Studies" and October 24, 2007 "Active Biotech"s Cancer Project ANYARA Proven Safe in Combination with Taxotere®", now detailed in JCO. About ANYARA ANYARA is a TTS (Tumor Targeting Superantigens) compound that makes the treatment of cancer tumor-specific. The development of ANYARA is mainly focused on renal cell cancer. Positive data was reported in connection with the interim analysis in Phase II/III and from clinical Phase I trials in lung cancer, renal cell cancer and pancreatic cancer. The median survival of 26.2 months observed for patients with advanced renal cancer and treated with ANYARA is twice the expected length. ANYARA has been granted orphan-drug status by the EMEA for the indication renal cancer. Information concerning the ongoing clinical trial is available at http://www.activebiotech.com and http://www.clinicaltrials.gov. Active Biotech


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009